Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The 336 merged reexam decision

It very well could be, and I hope that it is, that the price of license and maybe even down the line royalty demands have become so demanding that the potential licensee decides to wait out a lot of the unknowns.

Add to that the J's settlement/non-settlement that occurred, the Quanta case, and the realization by many that this 336 reexam may take alot longer to finalize. Throw in with the shake up of the company leadership and the lack of any open information to the public and private sector and many will just play out the time game and as we see in our PPS so are the potential investors.

Those that signed up already may have seen a license as a good price compared to all the hassle of a legal fight and the legal expense, not to mention that they just realized that, as the patents stand, they were infringing and chose the quick and cheaper way out. Hopefully there is no longer, a cheap way out. JMHO.

Share
New Message
Please login to post a reply